Literature DB >> 22424011

Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy.

Micha T Maeder1, Hans Rickli, Matthias E Pfisterer, Stefano Muzzarelli, Peter Ammann, Thomas Fehr, Dietrich Hack, Daniel Weilenmann, Thomas Dieterle, Stephanie Kiencke, Werner Estlinbaum, Hans-Peter Brunner-La Rocca.   

Abstract

BACKGROUND: Incidence, predictors, and prognostic impact of worsening renal function (WRF) in elderly patients with chronic heart failure (HF) undergoing intensive contemporary medical therapy are unknown. METHODS AND
RESULTS: In 566 patients (age 77 ± 8 years) included in the TIME-CHF, serum creatinine (sCr) was repeatedly measured up to 6 months. Worsening renal function was classified as increase in sCr by 0.2 to 0.3 (WRFI), 0.3 to 0.5 (WRFII), or ≥0.5 mg/dL (WRFIII) within the first 6 months. Outcome events were assessed for 18 months.
RESULTS: The incidence of WRF I, II, and III was 12%, 19%, and 22%, respectively. Worsening renal function III was associated with increased mortality (hazard ratio 1.98 [95% CI 1.27-3.07, P = .002] vs no WRF), whereas WRF I/II was not. History of renal failure, spironolactone treatment, higher baseline dose, and higher maximal increase in loop diuretic dose were independently associated with the occurrence of WRF III, whereas angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and β-blocker use and allocation to N-terminal pro-B-type natriuretic peptide-guided management were not. Worsening renal function III was an independent predictor of death, death or hospitalization, and death or HF hospitalization also after adjusting for baseline characteristics.
CONCLUSIONS: One fifth of elderly patients with chronic HF experienced WRF III on 6-month intensive HF treatment. These patients had higher mortality, whereas patients with smaller sCr rises did not. Occurrence of WRF III was associated with high doses of loop diuretics and spironolactone use but not with other treatments. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424011     DOI: 10.1016/j.ahj.2011.12.003

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  23 in total

1.  Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study.

Authors:  Viera Stubnova; Ingrid Os; Morten Grundtvig; Dan Atar; Bård Waldum-Grevbo
Journal:  Cardiorenal Med       Date:  2017-01-20       Impact factor: 2.041

Review 2.  Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.

Authors:  Catherine N Marti; Gregg C Fonarow; Stefan D Anker; Clyde Yancy; Muthiah Vaduganathan; Stephen J Greene; Ali Ahmed; James L Januzzi; Mihai Gheorghiade; Gerasimos Filippatos; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-12-10       Impact factor: 15.534

3.  One-year survival and renal function recovery of acute kidney injury patients with chronic heart failure.

Authors:  Wen Zhang; Dan Wen; Yan-Fang Zou; Ping-Yan Shen; Yao-Wen Xu; Hao Shi; Jing Xu; Xiao-Nong Chen; Nan Chen
Journal:  Cardiorenal Med       Date:  2014-12-24       Impact factor: 2.041

4.  Biomarker Guided Therapy in Chronic Heart Failure.

Authors:  Hans-Peter Brunner-La Rocca; Sema Bektas
Journal:  Card Fail Rev       Date:  2015-10

Review 5.  B-type natriuretic peptide-guided treatment for heart failure.

Authors:  Julie McLellan; Carl J Heneghan; Rafael Perera; Alison M Clements; Paul P Glasziou; Karen E Kearley; Nicola Pidduck; Nia W Roberts; Sally Tyndel; F Lucy Wright; Clare Bankhead
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

6.  Evaluation of a Community Health Service Center-Based Intervention Program for Managing Chronic Heart Failure.

Authors:  Moli Gu; Yanlan Ma; Ti Zhou; Yunfeng Xia
Journal:  Balkan Med J       Date:  2016-01-01       Impact factor: 2.021

7.  Impact of admission liver stiffness on long-term clinical outcomes in patients with acute decompensated heart failure.

Authors:  Kazunori Omote; Toshiyuki Nagai; Naoya Asakawa; Kiwamu Kamiya; Yusuke Tokuda; Tadao Aikawa; Arata Fukushima; Keiji Noguchi; Yoshiya Kato; Hirokazu Komoriyama; Mutsumi Nishida; Yusuke Kudo; Hiroyuki Iwano; Takashi Yokota; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2018-12-06       Impact factor: 2.037

8.  Effect of renal function on prognosis in chronic heart failure.

Authors:  Adrián Ignacio Löffler; Thomas P Cappola; James Fang; Scott J Hetzel; Andrew Kadlec; Brad Astor; Nancy K Sweitzer
Journal:  Am J Cardiol       Date:  2014-10-23       Impact factor: 2.778

9.  Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction.

Authors:  Alberto Palazzuoli; Marco Pellegrini; Beatrice Franci; Matteo Beltrami; Gaetano Ruocco; Stefano Gonnelli; Gianni D Angelini; Ranuccio Nuti
Journal:  Intern Emerg Med       Date:  2014-08-03       Impact factor: 3.397

Review 10.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.